Denosumab biosimilar (Kpc Pharmaceuticals)

地舒单抗生物类似药 (昆药集团)

Report date: 2025/06/05 12:06:36

Base Information

Drug NameDenosumab biosimilar (Kpc Pharmaceuticals)
Drug Alias Name重组抗RANKL全人源单克隆抗体 (昆药集团)全人源RANKL单克隆抗体注射液 (昆药集团)MV-088
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsOsteoporosis, Postmenopausal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesKpc Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Kunheng Pharmaceutical Technology Co LtdKpc Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsOsteoporosis, Postmenopausal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A